Catalytic subunits of phosphoinositide-3-kinase (PI3K) play a critical role in growth factor signaling and survival by phosphorylating inositol lipids. We found that PI3K Class-IA p110a and p110b have distinct functions in myoblasts. Inhibition of p110a reduced insulin-like growth factor-I (IGF-I)-stimulated Akt activity and prevented IGF-I-mediated survival in H 2 O 2 -treated cells; in contrast, siRNA knockdown of p110b increased IGF-I-stimulated Akt activity. However, inhibition of p110b catalytic activity did not increase IGF-I-stimulated Akt activity, suggesting a role for p110b protein interactions rather than decreased generation of phosphoinositides in this effect. Increased Akt activity in p110b-deficient myoblasts was associated with diminished extracellular signal-regulated kinase (ERK) activation as well as ERK-dependent IRS-1 636/639 phosphorylation, findings we show to be independent of p110b catalytic function, but associated with insulin-like growth factor-I receptor (IGF-IR) endocytosis. We also report that IGF-I protects myoblasts from H 2 O 2 -induced apoptosis through a mechanism that requires p110a, but may be independent of Akt or ERK under conditions of Akt and ERK inhibition. These observations suggest that both p110a and p110b are essential for growth and metabolism in myoblasts. Overall, our results provide new evidence for the roles of p110 isoforms in promoting cellular proliferation and homeostasis, IGF-IR internalization, and in opposing apoptosis.
Members of the phosphoinositide-3-kinase (PI3K) class of enzymes generate phosphoinositol products that act as second messengers in a number of intracellular signaling cascades. 1 PI3K catalytic enzymes are categorized into three classes by their structure, substrate specificity, and lipid products. 2 Members of the Class-IA PI3Ks (a, b, and d) are heterodimers consisting of a 110-kDa catalytic subunit and an 85, 55, or 50-kDa regulatory subunit. 2, 3 Activation of PI3K leads to proliferation and pro-survival effects; however, dysregulation of PI3K signaling can promote aberrant proliferative signals leading to cellular transformation. [4] [5] [6] [7] Examination of the ubiquitously expressed PI3K Class-IA p110a and p110b catalytic subunits has revealed distinct and redundant roles for each depending on cellular context. [8] [9] [10] Heterozygous knock-in of catalytically-inactive p110a or pharmacological inhibition of p110a with a small-molecule inhibitor has been shown to negatively regulate growth, metabolism, and growth factor signaling in mice. 10, 11 p110b has been shown to mediate cell growth and development, DNA replication, insulin sensitivity, tumorigenesis, and G-protein-coupled receptor-activated signaling. [12] [13] [14] [15] Recently, a kinase-independent, scaffolding role of p110b has been suggested; indeed, this kinase-independent function may play a role in cell proliferation and clatharinmediated endocytosis. 13, 16 Mice doubly heterozygous for p110a and p110b showed mild glucose intolerance and reduced sensitivity to insulin challenge associated with p85 protein instability, but showed no difference in insulinstimulated Akt phosphorylation or activity in liver or muscle as compared with control mice. 17 Insulin-like growth factor-I (IGF-I) is a hormone that promotes proliferation, differentiation, and survival in a number of cells types, mediated principally through PI3K/Akt and Ras/Raf/MEK/ERK pathways. [18] [19] [20] IGF-I/PI3K signaling has been shown to promote survival in several apoptosisinducing models such as serum withdrawal and oxidative stress; [21] [22] [23] however, the specific PI3K and Akt isoforms involved in survival are yet to be established. Likewise, PI3K/ Akt-independent compensatory survival mechanisms have yet to be fully resolved. We report here that C2C12 myoblasts transfected with siRNA against p110a, p110b, or a combination of both, displayed differential phenotypes with respect to cell growth and PI3K-dependent signaling. Furthermore, we found that IGF-I stimulation differentially regulated Akt phosphorylation and activation in a PI3K and Akt isoformspecific manner, and that p110a was the principal Class-IA PI3K mediating IGF-I antiapoptotic actions. Finally, we report that knockdown p110b negatively regulates insulin-like growth factor-I receptor (IGF-IR) internalization and extracellular signal-regulated kinase (ERK) activation, which was associated with relief of feedback inhibition of PI3K-dependent signal transduction.
Results
Reduced cell proliferation in cells treated simultaneously with siRNA against p110a and p110b is associated with increased apoptotic markers, whereas reduced cell proliferation in cells treated with siRNA against p110b alone is not. We first determined that both p110a and p110b are expressed at the mRNA and protein level in C2C12 myoblasts (Figure 1a ), but that p110g and p110d were not expressed appreciably. In order to establish the efficacy of siRNA-mediated knockdown of p110a and p110b, cells were transfected with siRNA against p110a (si-p110a), p110b (si-p110b), or non-targeting control siRNA (si-Con). Addition of si-p110a resulted in B60-65% reduction in p110a mRNA, whereas addition of si-p110b resulted in B65% reduction in p110b mRNA (Figure 1b ). mRNA levels of p110b were unaffected by p110a knockdown, and mRNA levels of p110a were unaffected by p110b knockdown. To determine whether cell growth was affected by knockdown of p110a, p110b, or the combination (si-p110a þ b), cells were counted at 24 and 48 h after transfection. Addition of si-p110b and si-p110a þ b caused a reduction in cell number at 48 h for si-p110b (Po0.05) and at 24 and 48 h for si-p110a þ b (Figure 1c ). This reduction in cell number was associated with increased cleavage of caspase-3 and poly-(ADP)-ribosyl polymerase (PARP), a molecule downstream of caspase-3 and an indicator of apoptosis (Figure1d). 24 As knockdown of p110a can reduce PI(3,4,5)P3 levels, 11 and p110b may act to maintain basal levels of PI(3,4,5)P3, 10 we analyzed Akt (also known as protein kinase B), an AGC-kinase family member whose activation is known to be regulated by phosphoinositides. 25 Forty-eight hours after transfection, levels of phospho-Akt in the hydrophobic domain (Ser473/ 474/472 in Akt1, Akt2, and Akt3, respectively; hereafter referred to as S473) showed decreased phosphorylation after treatment with p110a; conversely, phospho-Akt Ser 473 levels were increased after treatment with si-p110b alone ( Figure 1e ). The levels of phosphorylated Akt did not correlate with total p85 levels, as reductions in total p85 were observed in p110a-and p110b-deficient cells, but were Figure 1 PI3K p110a and p110b are expressed in C2C12 myoblasts and reduction of p110b or p110a and b simultaneously reduced cell growth. (a) PI3K p110 catalytic subunit expression in myoblasts. Real-time PCR was used to determine mRNA transcript level as described under Materials and Methods. C t values were first normalized to invariant endogenous b-2 microglobulin (B2 M), and then values were expressed relative to p110a, which was arbitrarily set at 1.0. Inset: Detection of expressed p110 isoforms by western blotting. (b) Efficacy of RNAi-mediated knockdown of p110a and p110b was determined by real-time PCR using B2 M as a reference gene, as in panel a. Cells were reverse-transfected with 10 nM negative control siRNA (si-Con) or 5 nM siRNA against p110a (si-p110a) plus 5 nM si-Con, 5 nM p110b (si-p110b) plus 5 nM si-Con, or simultaneous transfection (co-transfection) with 5 nM p110a and 5 nM p110b (si-p110a þ b). Medium was changed to antibiotic-containing media 24 h after plating, and cells were harvested for RNA 24 h following media change (48 h after initial reverse transfection). Values are expressed relative to p110a, which was arbitrarily set at 1.0. Columns represent averages of two independent experiments and error bars indicate S.E.M. (c) Cells were reverse-transfected as described in panel b at day 0. Twenty-four and 48 h after plating, cells were trypsinized and counted with a hemocytometer and expressed as fold changes relative to initial plating density, which was set at 1.0. Asterisks next to treatments indicate significant difference at Po0.05 after two-way ANOVA followed by Bonferroni post-test. (d) Cells were transfected as described in panel b, and myoblasts were harvested for protein lysates 24 and 48 h after plating. western blotting was performed to analyze levels of caspase-3, PARP, and GAPDH as described under Materials and Methods. Uncleaved caspase-3 and PARP are labeled and cleaved caspase-3 and PARP are indicated by arrows. Numbers 1-8 (bottom) indicate lanes. The asterisk (*) next to the PARP image indicates protein ladder (98 kDa) that reacted with antibody in this and some subsequent runs. Abbreviations: C, non-targeting control siRNA; a, siRNA against p110a; b, siRNA directed against p110b; a þ b, siRNA directed against p110a co-transfected with siRNA directed against p110b. (e) Cells were treated and maintained as described in panel b. Western blots of various proteins involved in PI3K signal transduction are shown. Each blot is representative of two independent experiments. Abbreviations are identical to those described in panel d even further reduced when cells were treated simultaneously with si-p110a and si-p110b ( Figure 1e ).
RNAi knockdown of p110a reduces, and knockdown of p110b increases, IGF-I-stimulated Akt phosphorylation and activity. As IGF-I can mediate pro-survival effects through Akt, we sought to determine the responsiveness of p110a-and p110b-deficient cells to IGF-I. Addition of IGF-I to cells transfected with si-p110a, si-p110b, or si-p110a þ b resulted in increased Akt phosphorylation at the activation loop (Thr308/309/305 in Akt1, Akt2, and Akt3, respectively; hereafter referred to as T308). This increase was reduced in si-p110a-treated cells, but further increased in si-p110btransfected cells (Figure 2a ). IGF-I-stimulated phospho-Akt in cells treated with both si-p110a and p110b together was not statistically lower than si-Con cells treated with IGF-I ( Figure 2a ). As the sequences surrounding the Akt active site (T308) and hydrophobic motif (S473) residues are similar between isoforms, and because the antibody cannot discriminate between isozymes, we performed in vitro kinase assays to determine the relative contributions of each isoform. IGF-I-stimulated Akt1 activity was reduced in cells transfected with si-p110a and si-p110a þ b; conversely, Akt1 activity was increased in response to IGF-I in cells treated with si-p110b ( Figure 2b ). Only cells transfected with si-p110a alone showed reduced Akt3 activity, and there was no increase or decrease in Akt3 activity in cells transfected with either p110b or p110a þ b, respectively. Akt2 activity was unchanged by any treatment, and long exposures (shown in Figure 2b ) likely represent the background. Taken together, these data suggest that knockdown of p110a reduces IGF-I-stimulated Akt phosphorylation and activation of both Akt1, and Akt3. IGF-I-induced Akt1 activity was greater in si-p110b-transfected cells than IGF-Istimulated Akt1 activity in control cells, which correlated with increased Akt phosphorylation. Yet, IGF-I-stimulated Akt3 activity did not show this elevation, suggesting that the increase in total Akt phosphorylation may be the result of increased Akt1 activation in p110b-deficient cells. On the other hand, in cells transfected with si-p110a þ b, Akt1 activity was diminished, but Akt3 activity was not, suggesting that the increase in IGF-I-stimulated Akt phosphorylation in si-p110a þ b-treated cells as compared with si-p110a alone, reflects increased Akt3 activation. To test whether this increased Akt activity in p110bknockdown cells correlated with increased p110 association with components of the IGF-IR signaling complex, we performed immunoprecipitation experiments. Treatment of cells with IGF-I promoted p110a and p110b association with insulin receptor substrate-1(IRS-1) and IGF-IR at early time points following administration (Figure 3a , left). In p110adeficient cells, IGF-I-induced association of both p110a and p110b with IGF-IR and IRS-1 was reduced, whereas in p110bdeficient cells, association of p110a with IGF-IR and IRS-1 was enhanced (Figure 3a , right). Simultaneous knockdown of p110a and p110b prevented IGF-I-induced association of both p110a and p110b with IGF-IR and IRS-1. These findings suggest that IGF-I-induced association of p110a with IGF-IR and IRS-1 is enhanced when p110b levels are reduced. We next determined whether p110a or p110b deficiency affected IGF-I-stimulated PI(3,4,5)P3 production. IGF-I promoted PI (3, 4, 5) P3 generation from p110a and p110b immunoprecipitates, and this effect was reduced when cells were deficient in the respective isoform ( Figure 3b ). Levels of PI(3,4,5)P3 in IGF-I-treated cells transfected with si-p110b were intermediate between unstimulated and IGF-I-stimulated control cells. Altogether, these data suggest that Akt activation correlates with levels of the p110-IGF-IR complex, but in cells deficient in p110b, mechanisms other than PI(3,4,5)P3 production may contribute to elevated Akt activation.
Knockdown of p110b is associated with decreased ERK signaling and IGF-IR internalization. To further elucidate the mechanism whereby Akt phosphorylation and activity is increased in p110b-deficient cells, as well as to further characterize intracellular responses to p110 catalytic subunit deficiency, we examined other molecules involved in canonical IGF-I signaling pathway. In cells deficient in p110b alone, or deficient in p110a and p110b, we found that phosphorylation of ERK was reduced in the basal state as well as after stimulation with IGF-I ( Figure 4a ). Additionally, IGF-I-stimulated phosphorylation of IRS-1 at Ser 636/639 was attenuated under conditions of reduced p110b, a finding consistent with previous work suggesting dependence on ERK for IRS serine phosphorylation at this site. 26 To determine whether decreased ERK phosphorylation seen in p110b-deficient cells was due to an overall decrease in p110b protein levels or due to decreased catalytic activity, cells were treated with increasing concentrations of TGX-221, an inhibitor of p110b catalytic function. Addition of TGX-221 reduced LPA-induced Akt phosphorylation in a dose-dependent manner, but did not affect IGF-I-stimulated ERK phosphorylation at any concentration tested ( Figure 4b ). These data suggest that the decreased levels of phosphorylated ERK observed in p110b-deficient cells may result from a loss of total p110b rather than loss of catalytic function, a finding consistent with a scaffolding action of p110b.
To address whether this catalysis-independent function of p110b mediates IGF-IR internalization, we examined the presence of IGF-IR at the cell surface after IGF-I treatment in the absence or presence of TGX-221 or si-p110b. Treatment of myoblasts with IGF-I resulted in a reduction in cell-surface IGF-IR that was maximal after 30 min (Figure 4c , left). In IGF-I-stimulated cells pretreated with 100 nM TGX-221, IGF-IR internalization was similar to IGF-I treatment alone; however, in cells deficient in p110b, IGF-IR did not internalize in response to IGF-I (Figure 4c , right). These findings suggest that at least one kinase-independent role of p110b in myoblasts is to mediate IGF-IR internalization.
IGF-I acts through PI3K p110a to prevent H 2 O 2 -induced apoptosis.
To establish whether the differential signaling effects of p110a and p110b knockdown extend to physiological actions in a proapoptotic milieu, cells were examined to determine whether knockdown of p110 isoforms was sufficient to inhibit IGF-I from preventing oxidative stress-induced cell death. To first test this, we employed an inhibitor specific to PI3K p110a (p110ai), 27 To confirm these results, we employed siRNA directed against p110a and p110b. Cells were pretreated with IGF-I, treated with H 2 O 2 , or both in the presence or absence of si-p110a, si-p110b, or si-p110a þ b. Similar to the inhibitor results, IGF-I was unable to prevent H 2 O 2 -induced cleavage of caspase-3 and PARP in cells deficient in p110a whether transfected with si-p110a alone (Figure 5d , left) or in combination with si-p110b (Figure 5d , right). Cells pretreated with si-p110b appeared partially resistant to H 2 O 2 -induced apoptosis (Figure 5d , middle), possibly a result of increased Akt activation ( Figure 2 ). Taken together, these data suggest that IGF-I acts through PI3-K p110a isoform to prevent H 2 O 2induced apoptosis in myoblasts exposed to oxidative stress.
Since reduction of p110b effectively inhibited phosphorylated ERK levels while simultaneously increasing Akt activation, we next tested whether Akt was a primary survival intermediate in p110b-knockdown cells. Maximal inhibition of IGF-I-stimulated phosphorylation of Akt S473 was obtained at a concentration of 10 mM using a compound specific for Akt (Akti; reference Barnett et al.; 28 Figure 5e , left). IGF-I was unable to prevent H 2 O 2 -induced apoptosis in p110b-transfected cells (Figure 5e , right) also treated with Akti, thus confirming that a functional Akt pathway is necessary for survival in p110b-deficient myoblasts. Figure 4 p110b knockdown, but not catalytic inhibition, reduces IGF-I-mediated ERK phosphorylation and IGF-IR internalization. (a) Cells were reverse-transfected and maintained as described in Figure 1b . Forty-eight hours after transfection, cells were harvested or treated with 125 ng/ml IGF-I for 30 min and then harvested for protein lysates. Western blotting was performed using antibodies indicated to the right of the respective images. Blots are representative of two independent experiments. (b) 95% confluent C2C12 myoblasts were pretreated with TGX-221 at the indicated concentrations for 1 h before addition of 20 mM LPA or 125 ng/ml IGF-I for 30 min. Western blots using the antibody against the indicated protein were then performed. (c) Quantity of IGF-IR at the cell surface after IGF-I administration was determined by biotin labeling and immunoprecipitation of surface proteins. Left panel: Cells were treated with 125 ng/ml IGF-I for the indicated times, labeled with sulfo-NHS-SS-biotin, and isolated according to the procedure described under Materials and Methods. The amount of IGF-IR located at the cell surface determined by western blotting after immunoprecipitation with NeutrAvidin Agarose; levels of total IGF-IR and GAPDH were determined by analyzing total cell lysate prior to immunoprecipitation. Columns represent quantified levels of surface IGF-IR divided by total IGF-IR normalized to untreated control, which was set at 1.0. Right panel: Cells were treated with 125 ng/ml IGF-I for 30 min after pretreatment with negative control siRNA (unlabeled) for 48 h, si-Con for 48 h, and TGX-221 for 1 h ('TGX-221'), or 5 nM siRNA against p110b ('si-p110b') for 48 h. Surface and total levels of indicated proteins were determined as described above. Columns represent quantified levels of surface IGF-IR divided by total IGF-IR from two independent experiments normalized to untreated control, which was set at 1.0. Asterisk indicates significant difference from unstimulated cells as determined by ANOVA with Tukey's HSD test post hoc (Po0.05). Error bars represent SD phosphorylation of p42/p44 ERK at 30 min, and 4.5 h after IGF-I administration, levels of phospho-ERK remained slightly below that of IGF-I-naive cells (Figure 6a , left). Cells treated with si-p110a or si-p110a þ b were pre-incubated with either Akti or U0126 and then stimulated with IGF-I for 4.5 h. Pharmacological blockade of MEK in IGF-I-treated p110adeficient cells prevented IGF-I-induced survival, and blockade of Akt increased p110a-deficiency-induced apoptosis beyond that of the MEK inhibitor (Figure 6a, right) . However, in p110a þ p110b-deficient cells, inhibition of Akt, but not MEK, fully prevented IGF-I pro-survival signaling. These data suggest that when p110a, and by extension Akt activation, is reduced, IGF-I survival signaling compensates by increased flux through the MAPK pathway. On the other hand, when cells are deficient in both p110a and p110b, IGF-I signals primarily through Akt to promote survival.
As IGF-I differentially acts through Akt and MEK pathways to promote survival from p110a and p110a þ p110b-deficiency-induced apoptosis, we sought to determine whether these pathways were also involved in preventing H 2 O 2induced apoptosis. Blockade of Akt, ERK, or concurrent inhibition of both, did not prevent IGF-I from inhibiting caspase-3 or PARP cleavage (Figure 6b ). These data suggest that, although Akt and ERK pathways can compensate for each other in response to IGF-I, at least one more mechanism exist through which IGF-I can exert antiapoptotic effects in response to oxidative stress in myoblasts.
Discussion
In this work, we report that myoblasts deficient in p110a and/or p110b show disparate growth and intracellular signaling phenotypes, corresponding with differential regulation of Akt and ERK signaling pathways. One key observation was that knockdown of p110a inhibited, but knockdown of p110b promoted, the activation of Akt in an isoform-specific manner. Although p110b may play a secondary role in growth factor signaling by maintaining a basal pool of PI (3, 4, 5)P3, 10, 13 it is not generally thought to play a primary role in RTK-instigated signaling except under certain conditions such as PTEN loss, or in certain cell types. 2, 29 Our results suggest that p110b deficiency leads to increased Akt activation through two separate mechanisms: First, reduced p110b levels enhance the IGF-I-induced association of p110a with IGF-IR and IRS-1. Second, reduced p110b levels inhibit phosphorylation of ERK and IRS-1 at S636/639, thereby relieving IRSassociated negative feedback. One intriguing finding was that increased IGF-I-stimulated Akt activation in p110b-deficient cells did not correlate with increased PI(3,4,5)P3 production, a finding consistent with previous results using skeletal muscle of insulin-stimulated p110a þ /À /p110b þ /À mice. 17 Those authors suggested that decreased p85 levels may contribute to insulin sensitivity, and indeed, in our study we observed lowered p85 in p110b-deficient cells (Figure 1e ).
Furthermore, our finding that serine phosphorylation of IRS-1 at Serine 636/639, a site dependent on ERK, 26 is reduced, is consistent with a relief of negative PI3K-signaling feedback. 30 Since IGF-I-stimulated Akt activity did not statistically differ between control and p110a þ p110b-deficient cells (Figure 2b ), yet there being virtually no p110/IGF-IR/IRS-1 association (Figure2c, right) , the loss of feedback inhibition in p110a þ p110b-deficient myoblasts may explain the mechanism underlying the similarity in Akt activation. Indeed, in skeletal muscle of insulin-stimulated p110a þ /À /p110b þ /À mice, Akt phosphorylation was similar to that observed in muscle of insulin-treated, wild-type mice. It is possible that other mechanism(s) contribute to increased Akt activation in p110b-deficient cells, including decreased actions of Aktspecific phosphatases, 31, 32 but whether activation of these phosphatases is reduced under these conditions remains to be investigated. Altogether, our observations suggest that increased IGF-I-stimulated Akt activity in p110b-deficient myoblasts may result from both an increase in p110a/IRS-1/ IGF-IR association as well as decreased negative feedback to IRS-1 secondary to reduced ERK activation. That distinct Akt isoforms are differentially regulated suggests a high degree of fine-tuning in these processes. Figure 7 presents this signaling model diagrammatically.
The lower levels of ERK phosphorylation in p110b-deficient cells may be reflective of decreased association of p110b with Ras, an upstream molecule in the MAPK signaling pathway; indeed, ERK activation has been shown to be attenuated under conditions where p110b cannot bind to Ras. 4, 5 However, use of TGX-221, a compound that inhibits p110b catalytic activity, did not prevent ERK phosphorylation in response to IGF-I in this study. These results suggest that non-catalytic functions of p110b may be essential for ERK activation in myoblasts; in support of this, cells deficient in p110b also showed decreased IGF-IR internalization in addition to attenuated ERK signaling. This is in agreement with previous work suggesting requirement for IGF-IR internalization for activation of upstream MAPK pathway components in CHO cells; 33 additionally, p110b itself has been shown to modulate EGFR and transferrin uptake. 13, 16 Taken together, these data and ours support the hypothesis of a kinase-independent function of p110b in IGF-IR internalization and signaling. Consequently, p110b may play a role in IGF-I-mediated processes in skeletal muscle such as progenitor cell proliferation, survival, and differentiation, which occur during muscle development and repair/regeneration.
In light of the above findings, it was not surprising that inhibition of p110a by means of pharmacological blockade or siRNA completely prevented IGF-I from reducing caspase-3 and PARP cleavage in response to H 2 O 2 , whereas TGX-221or RNAi-induced silencing of p110b did not (Figure 5a-d) . Akt is a critical mediator of antiapoptotic signaling, acting to suppress apoptosis by phosphorylation and inactivation of proapoptotic molecules such as apoptosis-signal-regulating kinase-1 (Ask1), 34 Bad, 35 and FoxO3a. 36 As Akt signaling was reduced after p110a knockdown or treatment with p110ai, it would logically follow that suppression of Akt-targeted proapoptotic molecules would also be attenuated. Likewise, because Akt activation was elevated with p110b knockdown, and this was found to be necessary for survival, IGF-Istimulated Akt actions would also be elevated.
Myoblasts deficient in p110a or p110a and p110b together showed increased caspase-3 and PARP cleavage, an effect fully reversed by IGF-I. We found that inhibition of MEK prevented IGF-I from attenuating p110a-deficiency-induced caspase-3 and PARP cleavage, and that inhibition of Akt caused apoptosis in excess of p110a deficiency alone. Inhibition of Akt, but not MEK, prevented IGF-I from attenuating p110a þ p110b-deficiency-induced caspase-3 and PARP cleavage (Figure 6a ). These data suggest that IGF-I can act through an MEK-dependent pathway to rescue cells from apoptosis associated with p110a deficiency, but that myoblasts under these conditions are more sensitive to loss of Akt, possibly resulting from the reduced Akt activation associated with p110a deficiency. Likewise, in cells simultaneously deficient in p110a and p110b, blockade of Akt prevented IGF-I from opposing apoptosis, whereas blockade of MEK had minimal effects. This is consistent with our findings that ERK activation is inherently reduced under conditions of p110b deficiency, whether alone or in combination with p110a reduction.
We found that IGF-I was still able to prevent H 2 O 2 -induced apoptosis even under conditions of Akt and MEK blockade. However, our results also suggest a dependence on p110a. Therefore, our data collectively suggest that IGF-I is capable of preventing H 2 O 2 -induced apoptosis through an Akt-and MEK-independent, but p110a-dependent, mechanism. Since other AGC kinases are also regulated through p110a in response to IGF-I, it is possible that one or several may contribute to opposing apoptosis. For example, serum-and glucocorticoid-inducible kinase-1 (SGK1) can phosphorylate and inhibit proapoptotic FoxO3a at the same sites as Akt, although there exists a preference for some sites over others. 37 In conclusion, we found that knockdown of p110a and p110b have differential effects on cell growth, survival signaling, and Akt activation. We have defined a kinaseindependent role for p110b in IGF-IR internalization and ERK phosphorylation, which is associated with negative feedback to the IGF-IR/IRS-1 signaling complex. Additionally, we identified p110a as the primary Class-IA PI3K involved in IGF-I-mediated rescue from oxidative stress-induced apoptosis and that, in the absence of Akt and MEK-dependent signaling, IGF-I can still prevent H 2 O 2 -induced apoptosis, but through a mechanism that requires p110a.
Materials and Methods
Materials. C2C12 murine myoblasts were purchased from ATCC (Manassas, VA, USA). H 2 O 2 and bovine serum albumin (fraction V) was purchased from Sigma (St Loius, MO, USA). rhIGF-I was purchased form Austral Biologicals (San Ramon, CA, USA). Primary antibodies directed against p110b and GAPDH, and HRP-linked secondary antibodies were purchased from Santa Cruz (Santa Cruz, CA, USA); all other antibodies were obtained from Cell Signaling Technologies (Danvers, MA, USA). PI3Ka inhibitor-IV ('p110ai' in this paper, corresponds to Figure 15e in reference Hayakawa et al. 27 ), TGX-221, Akt 1/2 inhibitor VIII ('Akti'), and U0126 were purchased from Calbiochem (San Diego, CA, USA). LPA (18 : 1 oleoyl) was purchased from Avanti Polar Lipids (Alabaster, AL, USA).
Cell culture conditions and siRNA transfections. C2C12 myoblasts were maintained in high-glucose DMEM containing 10% FBS and antibiotics (growth medium), with medium being replenished after 24 h. Forty-eight hours after initial seeding cells were B95% confluent and unless otherwise indicated, experiments were conducted under these conditions (in growth medium). Predesigned Silencer Select siRNAs for mouse p110a (ID no. s71604), p110b (ID no. s93108), and negative controls (non-targeting siRNA, ID no. 4390843) were purchased from Ambion Inc. (Austin, TX, USA). Cells (1.8 Â 10 5 /well in six-well culture dish) were reverse-transfected with double-stranded siRNA in antibiotic-free DMEM plus 10% FBS using Lipofectamine 2000 according to manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). Twenty-four hours after reverse transfection, medium was changed to DMEM with 10% FBS containing antibiotics. RNA was isolated 48 h after transfections using RNA-STAT (Tel-test, Friendswood, TX, USA), quantified, and the level of silencing quantitated by real-time PCR as described later in this section. In some cases, protein was isolated 48 h after transfection and the level of silencing determined by western blotting.
Cell counts. Medium was removed from plates and monolayers detached with 0.05% trypsin-EDTA (Gibco, Carlsbad, CA, USA). Cells were suspended in growth medium and counted in a hemacytometer chamber.
RNA Isolation, cDNA synthesis, and real-time PCR. Conversion of total RNA to single-stranded cDNA was accomplished using the High-Capacity cDNA Archive kit (P/N 4322171; Applied Biosystems, Foster City, CA, USA). Briefly, 2 mg total RNA was reverse transcribed using random primers for the following incubation times: 251C for 10 min, then 371C for 2 h. cDNA samples were stored at À801C until use. TaqMan-MGB p110a (Mm00435673_m1), p110b (Mm00659576_m1), p110g (Mm00445038_m1), p110d (Mm00435674_m1), and B2M (Mm00437762_m1) probe and primers were purchased from Applied Biosystems as 'Gene Expression Assays.' Real-time PCR reaction was performed within an ABI 7500 thermal cycler. The fluorescence of 3-15 cycles was set up as background. Data were collected at the annealing step of each cycle, and the threshold cycle (C t ) for each sample was calculated by determining the point at which the fluorescence exceeded the threshold limit. The standard curve was generated automatically using a software by plotting the C t values against each standard of known concentration and calculation of the linear regression line of this curve. Serially diluted amounts of RNA were used to establish standard curves. All samples were run in duplicate.
Protein extraction, immunoprecipitation, and Western
Immunoblotting. C2C12 cells were harvested in ice-cold lysis buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na 3 VO 4 , 1mg/ml leupeptin, 1 mM PMSF, and 1 : 100 dilution of phosphatase inhibitor cocktails 1 and 2 (Sigma)). Homogenates were triturated through a small-bore needle, incubated on ice for 30 min, and centrifuged at 14 000 Â g for 10 min at 4 1C. Protein concentrations were determined by Bradford method. 38 For immunoprecipitations, 200 mg of protein lysate were co-incubated with 4 ml of respective antibody in 200 ml cell lysis buffer with gentle rotation overnight at 4 1C. A 20-ml of Protein-A/G agarose slurry (Santa Cruz) was then added and rotated an additional 2-4 h at 41C. Complexes were centrifuged at 14 000 Â g and washed five times in wash buffer before addition of 20 ml 2 Â Laemmli buffer and then boiled for 5 min. For western blotting, equal amounts of cell lysate proteins (typically 25 mg) were electrophoresed through denaturing SDS-PAGE. Proteins were transferred to PVDF membranes (Millipore Corp., Bedford, MA, USA). Membranes were incubated for 1 h in 5% dry milk solution in Tris-buffered saline plus 0.5% Tween-20 (TBST) and then incubated with the appropriate primary antibody at an appropriate dilution overnight in 5% BSA in TBST. Membranes were washed three times in TBST followed by incubation with the appropriate secondary antibody and again washed three times. Membranes were incubated with enhanced chemiluminescence reagents (Thermo Fisher, Rockford, IL, USA) and exposed to film. confluent myoblasts were pretreated with 0.1% DMSO or increasing concentrations of Akti for 1 h before addition of IGF-I for 4.5 h. Western blotting was performed using the indicated antibodies. Right panel: Cells were reverse-transfected with siRNA against p110b as described above in panel d. Forty-eight hours following transfection, some cells were pre-incubated with 10 mM Akti. Following the 1 h incubation period, cells were treated with 400 mM H 2 O 2 for 4 h before harvest and western blotting with the indicated antibodies. Blots are representative of two independent experiments provided quenching solution. Cells were transferred to 50-ml conical tubes, centrifuged, and washed with TBS. Lysis buffer provided in the kit was added to cell pellets and transferred to microfuged tubes and briefly sonicated every 10 min for 30 min at a power of 1.5 followed by clarification of supernatant, which was quantified and 1.4 g added to provided spin columns. At this point, some protein lysate was stored at À801C for analysis of total IGF-IR or GAPDH. Biotin-labeled proteins were washed and isolated with NeutrAvidin Agarose (provided in the kit) with end-over-end mixing for 1 h. Agarose/biotinylated complexes were washed and incubated in sample buffer (62.5 mM Tris (pH 6.8), 2% SDS, 20% glycerol) for 1 h, centrifuged, and the eluate was collected. A small amount of bromophenol blue was added to eluate and proteins were separated by SDS-PAGE followed by western blotting for IGF-IR or GAPDH as described above.
Detection of PI (3, 4, 5) P3. Levels of PI(3,4,5)P3 were determined by using a commercially available ELISA assay (Echelon Biosciences, Salt Lake City, UT, USA; P/N K-1000) following the manufacturer's instructions. Briefly, after treatment, cells were washed three times in Buffer A (20 mM Tris-HCl (pH 7.4), 137 mM NaCl, 1 mM CaCl 2 , 1 mM MgCl 2 , and 0.1 mM sodium orthovanadate) and incubated at 41C for 30 min in Buffer A plus 1% NP-40 and 1 mM PMSF. Insoluble material was removed by centrifugation and clarified lysates quantified. A 125-mg weight was immunoprecipitated with either p110a or p110b antibody for 2 hours at 41C, followed by mixing with Protein-A/G agarose beads (Santa Cruz) for 1 h. Immunocomplexes were washed three times with Buffer A plus 1% NP-40, three times with 0.1 M Tris-HCl (pH 7.4); 5 mM LiCl, and 0.1 mM sodium orthovanadate, and twice in TNE (10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 5 mM EDTA, and 0.1 mM sodium orthovanadate). Kinase reactions were performed in triplicate by incubation in PI3K reaction buffer (20 mM Tris (pH 7.4), 10 mM NaCl, 4 mM MgCl 2 , and 25 mM ATP) and 100 mM PI(4,5)P2 substrate for 2 h, followed by centrifugation to stop the reactions and addition of PI(3,4,5)P3 detector for 1 hour. At this time, PIP3 standards (provided) were set up using concentrations of 200, 100, 50, 25, 12.5, and no lipid control. Reacted mixtures and standards were then transferred to the detection plate for 60 min, washed once in TBS-T, and secondary detector added for 30 min. Wells were washed three times with TBS-T and then 100 ml of TMB solution added to induce color change. Color development was stopped by addition of 1 N H 2 SO 4 stop solution when color development was within the linear range of standards, followed by reading at 450 nM.
Statistics. Data are presented as means ± S.E.M. Statistics were performed using either one-way or two-way ANOVA and multiple range tests a posteriori, as described in the figure legends. Densiometric analysis was performed using Image J 1.60 (http://rsbweb.nih.gov/ij/). A P-value o0.05 was considered significant.
Figure 7
Proposed mechanism of IGF-I signal transduction in myoblasts. Signaling through IGF-IR recruits adaptor molecules including IRS-1 to IGF-IR. This promotes binding of PI3K and generation of 3 0 lipid phosphoinositides that recruit other molecules, including Akt, to the membrane, ultimately resulting in their activation. PI3K p110a catalytic subunit is required for Akt activation, but p110b is not. A second pathway includes non-catalytic action of p110b that is associated with IGF-IR internalization and is required for activation of ERK. ERK may then phosphorylate IRS-1 at Ser 636/639, inhibiting PI3K binding and promoting IRS-1 degradation, thus attenuating IGF-IR signals
